The present invention relates to host cells comprising genes of the mevalonate and linalool pathways, methods as well as kits for producing linalool.

The present invention relates to host cells comprising genes of the mevalonate, lycopene and -ionone pathways and the hydroperoxide reductase or catalase genes. The present invention also relates to methods of producing apocarotenoids as well as kits for producing apocarotenoids comprising the host cells.

The present invention relates to host cells comprising genes of the mevalonate and Nudix pathways, engineered fusion proteins of enzymes of the mevalonate and Nudix pathways, methods as well as kits for producing geraniol and geranyl acetate.

A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

The invention disclosed herein relates generally to the field of recombinant production of a steviol glycoside, to the field of bioconversion of steviol into a steviol glycoside and to the field of bioconversion of a steviol glycoside into a further steviol glycoside. Particularly, the invention provides a process for recombinant production of a steviol glycoside, a process of bioconversion of steviol into a steviol glycoside, a process for bioconversion of a steviol glycoside into a further steviol glycoside and a composition comprising a steviol glycoside. More particularly, the invention relates to a microorganism that has a deficiency of a serine/threonine protein kinase and comprises a polynucleotide encoding a polypeptide having uridine diphosphate-dependent glucosyltransferase (UGT) activity.

Disclosed are production of terpenoid compound and the strain used by, which belong to the technical field of bioengineering. The disclosure constructs an engineered strain of Serratia marcescens in production of hemiterpenes or monoterpenes, and the engineered strain of S. marcescens can produce linalool, isoprene, isopentenol, 1,8-cineole, -pinene, pinene, -terpinene, geraniol, (+)-limonene, ()-limonene, myrcene, -ocimene, sabinene, ()--bisabolol, farnesol, longifolene, valencene, -elemene, farnesene, patchoulol, pentalenene, and -santalene. In a 30 L fermenter, the yield of linalool produced by the engineered strain of S. marcescens is 40.72 g.Math.L.sup.1.

Disclosed herein are novel prenyltransferases for the production of cannabinoids, as well methods of making and using such prenyltransferases.

A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.

The present disclosure relates generally to methods and compositions for activating gamma-delta (GD) T cells. Such methods and compositions can be used to treat cancer.